

UCLA

Proceedings of UCLA Health

Title

Remission Achieved with Tacrolimus in a Patient with ISN-RPS Class V Lupus Membranous Glomerulonephritis Unable to Tolerate Mycophenolate Mofetil

Permalink

<https://escholarship.org/uc/item/23s7d973>

Journal

Proceedings of UCLA Health, 22(1)

Authors

Hanna, Ramy M

Kaldas, Marian

Wallace, William D

Publication Date

2018-04-12

CLINICAL VIGNETTE

Remission Achieved with Tacrolimus in a Patient with ISN-RPS Class V Lupus Membranous Glomerulonephritis Unable to Tolerate Mycophenolate Mofetil

Ramy M. Hanna, MD, Marian Kaldas, MD and William D. Wallace, MD

Case Report

A 33-year-old Japanese American woman was admitted with facial swelling and diarrhea. She had multiple prior admissions to an outside hospital for presumed sinusitis. She was thought to have pan-colitis due to *Clostridium difficile*, but repeat testing was negative for *C. Diff* antigen. She had a history of hypothyroidism with positive markers for autoimmune Hashimoto's Thyroiditis. Notably, there was no history of pregnancy loss, pre-eclampsia, or other thromboembolic events prior to her admission.

The patient had low complement levels (C3=23mg/dL, C4=4 mg/dL, CH50=13 mg/dL), positive anti-nuclear antibody at 1:1280 units homogenous pattern, and anti-ds DNA antibody of 344 IU/ml. These serological findings were suspicious for systemic lupus erythematosus. A pericardial effusion, pleural effusions, and a small pulmonary embolism were found on further testing. Alopecia, proteinuria, and severe hemolytic anemia (with decrease of hemoglobin to 6.7 g/dL) were also noted. The patient met definition for SLE disease activity using the newer SLICC criteria.¹ Dilute Russel Viper Venom Time (DRVVT) and anti-cardiolipin antibody levels obtained before anticoagulation were non-conclusive and remained borderline after; therefore they were not diagnostic of antiphospholipid antibody syndrome. The DRVVT test initially showed no endpoint detected and was subsequently borderline on anticoagulation. Though, the anti-cardiolipin antibody IgA and IgG were negative when tested twice while the anti-cardiolipin IgM level was low level positive at 56.5 MPL and decreased to 21.6 MPL subsequently on anticoagulation therapy.

Initial renal workup was notable for severe proteinuria at 3.8-6.7 grams protein/gram creatinine. Her rivaroxaban anticoagulation for pulmonary embolism was held prior to renal biopsy. Two core biopsies with 12 total glomeruli were globally abnormal and showed sub-epithelial spikes with mild mesangial proliferation and sub-epithelial basement membrane deposits. The immunofluorescence showed positive "full house" capillary wall and mesangial staining for IgG (3-4+), IgA (1-2+), IgM (1-2+), C1q (3-4+), C3 (1-2+), and both light chains (1-2+). In total, the staging of the patient's ISN-RPS Class V SLE membranous nephropathy was graded at stage II/IV without evidence of interstitial inflammation, crescent formation, or fibrosis.² (See Figure 1).




Figure 1: Pertinent biopsy slides demonstrating class II/IV lupus membranous glomerulonephritis (ISN-RPS Class V). A) Light microscopy showing thickened basement membranes with subepithelial spikes due to membranous nephropathy (Jones methenamine silver stain; original magnification 400x). B) Immunofluorescence (IF) showing strong granular staining in capillary walls and mesangial regions for IgG. IgA, IgM, C1q, C3 and kappa and lambda light chains were also noted on IF demonstrating "full house" seen in LN. C) Electron micrograph showing subepithelial basement membrane spikes in between deposits on glomerular basement membrane, typical of membranous nephropathy, including Class V LN.

The patient was placed on mycophenolate mofetil and high dose 1mg/kg prednisone during her initial admission. She was readmitted 2 months later with worsening proteinuria up to 13 grams of protein/gram creatinine on spot urine protein to creatinine ratio. The patient also continued to suffer from diarrhea despite antibiotic treatment and underwent extensive gastroenterological workup including esophagogastroduodenoscopy and colonoscopy. After *Clostridium difficile* colitis was excluded she was felt to have the presumptive diagnosis of mycophenolate associated colitis. However, biopsy specimens showed only mild nonspecific interstitial infiltrates. A Cytomegalovirus (CMV) Polymerase Chain Reaction (PCR) in the blood was positive at 1,746 IU/ml and suggested another possible cause for her chronic diarrhea.

Nevertheless, the ongoing diarrhea in conjunction with the flare of LN necessitated new therapy. She was started on CMV treatment with valgancyclovir and tacrolimus dosage was modified with goal of a 12 hour trough level of 5-7 ng/ml. Her proteinuria immediately decreased and her hemolytic anemia resolved. Diarrhea resolved after treatment for CMV. The patient has continued to do well on warfarin anticoagulation, tacrolimus, and valgancyclovir. Her protein level decreased from a peak of 13 grams to a nadir of 0.4-0.6 grams/gram creatinine, achieving complete remission (defined as <0.5grams protein/gram creatinine).

Her electrolytes and serum creatinine have remained at baseline, and anti-DS DNA antibody titers, which correlate with LN disease activity, have become undetectable. The patient has experienced no further clotting events on warfarin which remains therapeutic with very close monitoring. (See Figure 2).




Figure 2: Plot of trends of serum creatinine (mg/dL), urine protein to creatinine ratio (grams protein/gram creatinine), and anti-ds DNA titer levels (IU/ml). Red arrow mycophenolate therapy started dashed green arrow mycophenolate therapy stopped. Blue arrow tacrolimus therapy started. Please see attached figure legend.

Discussion

Systemic Lupus Erythematosus (SLE) is a devastating disease that can target various organ systems including the nervous system, heart, lungs, hematopoietic system, and kidneys.³ Variation in the disease of lupus range from cutaneous-only manifestations to severe life threatening disease such as lupus-cerebritis or coagulopathy including catastrophic antiphospholipid antibody syndrome, and end stage renal disease from rapidly progressive diffuse proliferative glomerulonephritis.⁴ The pathophysiology behind SLE is due to loss of tolerance to some self-antigens and auto-immune activation with auto-antibodies identified against various nuclear antigens including deoxyribonucleic acids.⁵ These antigens are not normally exposed and as such may not be as protected by selection against self-reactive B and T cells that occurs as the thymus and bone marrow progenitor cells mature.⁶ One reason systemic lupus erythematosus is more common in females is the interaction of female sex hormones such as estrogen with the immune system and the upregulation of some interferons.⁷ There are other differences in incidence and clinical presentations as well as reliability of current indicators seen in SLE that differ according to genetics and environmental exposures in different ethnic groups.⁸

Lupus nephritis (LN) is one of the most worrisome complications of SLE, with an increased risk of mortality and morbidity in patients. The general standard has been to obtain a renal biopsy when signs of active glomerulonephritis are detected, namely proteinuria near or greater than 0.5-1 gram/day with hematuria, and/or unexplained worsening of renal function.⁹ The current classification system for patho-

logical findings on biopsy has been refined from the older World Health Organization (WHO) system to the newer International Society of Nephrology-Renal Pathology Society (ISN-RPS) scale.⁸ The two systems are comparable but the ISN-RPS scale adds the designation of class VI for diffuse sclerosis in cases of advanced lupus nephritis, as well as various sub-classifications for refined pathological characterization.⁸

The classification is based on the location and intensity of the immune complex deposits and the degree of glomerular changes. The mildest manifestation of disease is minimal mesangial (class I) or mesangial (class II) lupus nephritis. Focal proliferative and diffuse proliferative glomerulonephritis (FPGN and DPGN) are the more severe forms of active disease (Class III and IV, respectively). These are due to sub-endothelial deposits, in class III LN, the changes affect less than 50% of glomeruli and in class IV, the glomerular changes affect greater than 50% of glomeruli. Class V LN represents sub-epithelial immune complex deposition and is called membranous lupus nephritis. This is a distinct pathological entity and tends to present with sub-epithelial glomerular basement membrane spikes and is more commonly nephrotic rather than nephritic in presentation.¹⁰ Treatment has tended to be with mycophenolate mofetil or mycophenolic acid, though other alternatives can be considered in lupus nephritis. The antiCD20 monoclonal antibody Rituxamab and the calcineurin inhibitor (CNIs) have been used as adjunct/alternative treatments in this LN in the proliferative types of LN subtype as well this subtype. Class VI lupus nephritis represents end stage renal disease and is defined as greater than 90% glomerulosclerosis.

This patient with severe active lupus nephritis and severe nephrotic syndrome with proteinuria was unable to tolerate the standard therapy for LN including type V membranous glomerulonephritis due to SLE. However, the patient was able to tolerate the dosing of 2 mg of tacrolimus in AM and 1.5 mg of tacrolimus in PM and maintained through levels between 5 and 7 ng/ml with resulting control of proteinuria and great diminishing of SLE disease activity. Her dose is the current recommended dose for tacrolimus used to treat refractory SLE nephritis.¹¹ It is interesting her serum creatinine came up slightly with tacrolimus use but given how stable her levels have been between 5-7 we feel this is possibly also likely to her kidneys no longer hyper-filtering with the dramatic decrease in proteinuria (please see Figure 2). She remains in complete remission on this alternate treatment.

This supports the efficacy of calcineurin inhibitors (CNIs), widely used transplant immune-suppressants, in controlling SLE disease activity including LN.¹² This option should be considered as a second or third line agent in LN, but especially in class V membranous GN. Many studies have shown similar successes with use of CNIs in primary membranous nephropathy with less toxicity than the traditional alternatives (corticosteroids and cyclophosphamide).¹³ It is important to consider the risk of CNI toxicity, including renal vascular disease, and risk of relapse of SLE membranous LN once CNIs are stopped.¹⁴ Rituxamab may also be a useful adjunctive treatment in primary membranous nephropathy though it is also being tested in LN generally and Class V membranous LN as well.^{15,16}

REFERENCES

1. **Aringer M, Dörner T, Leuchten N, Johnson SR.** Toward new criteria for systemic lupus erythematosus—a standpoint. *Lupus*. 2016 Jul;25(8):805-11. doi:10.1177/0961203316644338. Review. PubMed PMID: 27252256.
2. **Mirza MK, Kim L, Kadambi PV, Chang A, Meehan SM.** Membranous nephropathy transplanted in the donor kidney: observations of resolving glomerulopathy in serial allograft biopsies. *Nephrol Dial Transplant*. 2014 Dec;29(12):2343-7. doi: 10.1093/ndt/gfu333. Epub 2014 Oct 23. Review. PubMed PMID: 25342301.
3. **Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, James JA.** Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. *Arthritis Rheum*. 2007 Jul;56(7):2344-51. Pub Med PMID: 17599763.
4. **Rosenbaum E, Krebs E, Cohen M, Tiliakos A, Derk CT.** The spectrum of clinical manifestations, outcome and treatment of pericardial tamponade in patients with systemic lupus erythematosus: a retrospective study and literature review. *Lupus*. 2009 Jun;18(7):608-12. doi: 10.1177/0961203308100659. Review. PubMed PMID: 19433460.
5. **Choi J, Kim ST, Craft J.** The pathogenesis of systemic lupus erythematosus—an update. *Curr Opin Immunol*. 2012 Dec;24(6):651-7. doi: 10.1016/j.coi.2012.10.004. Epub 2012 Nov 3. Review. PubMed PMID: 23131610; PubMed Central PMCID: PMC3508331.
6. **Zhang J, Jacobi AM, Wang T, Diamond B.** Pathogenic autoantibodies in systemic lupus erythematosus are derived from both self-reactive and non-self-reactive B cells. *Mol Med*. 2008 Nov-Dec;14(11-12):675-81. doi: 10.2119/2008-00066.Zhang. Epub 2008 Jul 30. PubMed PMID: 18677426; PubMed Central PMCID: PMC2493535.
7. **Yacoub Wasef SZ.** Gender differences in systemic lupus erythematosus. *Gend Med*. 2004 Aug;1(1):12-7. Review. PubMed PMID: 16115579.
8. **Lopez E, Hanna RM, Wilson J.** Decreased sensitivity of anti-dsDNA antibody assay observed in a cohort of Hispanic patients with biopsy-proven lupus nephritis. *Saudi J Kidney Dis Transpl*. 2016 Nov-Dec;27(6):1270-1273. PubMed PMID:27900979.
9. **Haladyj E, Cervera R.** Do we still need renal biopsy in lupus nephritis? *Reumatologia*. 2016;54(2):61-6. doi: 10.5114/reum.2016.60214. Epub 2016 Jun 3. Review. PubMed PMID: 27407281; PubMed Central PMCID: PMC4918045.
10. **Beck LH Jr, Salant DJ.** Treatment of membranous lupus nephritis: where are we now? *J Am Soc Nephrol*. 2009 Apr;20(4):690-1. doi: 10.1681/ASN.2009020216. Epub 2009 Mar 11. PubMed PMID: 19279123.
11. **Fei Y, Wu Q, Zhang W, Chen H, Hou Y, Xu D, Li M, Zhang X, Zhao Y, Zeng X, Zhang F.** Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. *Clin Exp Rheumatol*. 2013 Jan-Feb;31(1):62-8. Epub 2012 Aug 30. PubMed PMID: 22935463.
12. **Gordon S, Denunzio T, Uy A.** Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria. *Hawaii J Med Public Health*. 2013 Sep;72(9 Suppl 4):18-23. PubMed PMID: 24052913; PubMed Central PMCID: PMC3764582.
13. **Qiu TT, Zhang C, Zhao HW, Zhou JW.** Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials. *Autoimmun Rev*. 2017 Feb;16(2):136-145. doi: 10.1016/j.autrev.2016.12.005. Epub 2016 Dec 15. Review. PubMed PMID: 27988429.
14. **Jaryal A, Vikrant S.** Current status of lupus nephritis. *Indian J Med Res*. 2017 Feb;145(2):167-178. doi: 10.4103/ijmr.IJMR_163_16. Review. PubMed PMID: 28639592; PubMed Central PMCID: PMC5501048.
15. **Chavarot N, Verhelst D, Pardon A, Caudwell V, Mercadal L, Sacchi A, Leonardi C, Le Guern V, Karras A, Daugas E; Groupe Coopératif sur le Lupus Rénal.** Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. *Medicine (Baltimore)*. 2017 Jul;96(27):e7429. doi: 10.1097/MD.0000000000007429. PubMed PMID: 28682905; PubMed Central PMCID:PMC5502178.
16. **Beckwith H, Lightstone L.** Rituximab in systemic lupus erythematosus and lupus nephritis. *Nephron Clin Pract*. 2014;128(3-4):250-4. doi: 10.1159/000368585. Epub 2014 Nov 29. Review. PubMed PMID: 25471633.

Submitted April 12, 2018